Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 20,000 shares of the stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $203.27, for a total value of $4,065,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Illumina, Inc. (NASDAQ ILMN) traded up 0.75% during trading on Thursday, reaching $208.24. 657,641 shares of the company traded hands. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $214.34. The stock has a market capitalization of $30.40 billion, a P/E ratio of 41.78 and a beta of 0.76. The firm’s 50 day moving average is $204.12 and its 200-day moving average is $185.47.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. The business had revenue of $662.00 million for the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.86 earnings per share. On average, equities research analysts anticipate that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/12/insider-selling-illumina-inc-ilmn-director-sells-20000-shares-of-stock.html.

ILMN has been the subject of a number of recent research reports. Vetr downgraded Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price objective for the company. in a report on Wednesday, June 21st. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $195.00 price objective for the company in a report on Thursday, July 27th. Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and increased their price objective for the company from $170.00 to $215.00 in a report on Monday, August 7th. Argus increased their price objective on Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a report on Wednesday, September 13th. Finally, First Analysis upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price objective for the company in a report on Wednesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. Illumina currently has an average rating of “Hold” and a consensus price target of $187.85.

A number of institutional investors and hedge funds have recently made changes to their positions in ILMN. Municipal Employees Retirement System of Michigan grew its holdings in Illumina by 1.5% in the first quarter. Municipal Employees Retirement System of Michigan now owns 4,740 shares of the life sciences company’s stock worth $809,000 after purchasing an additional 70 shares during the period. Teachers Advisors LLC grew its holdings in Illumina by 60.7% in the first quarter. Teachers Advisors LLC now owns 384,300 shares of the life sciences company’s stock worth $65,577,000 after purchasing an additional 145,231 shares during the period. Massachusetts Financial Services Co. MA purchased a new stake in Illumina in the first quarter worth about $2,404,000. Cleararc Capital Inc. grew its holdings in Illumina by 1.3% in the first quarter. Cleararc Capital Inc. now owns 3,326 shares of the life sciences company’s stock worth $568,000 after purchasing an additional 44 shares during the period. Finally, Global X Management Co. LLC grew its holdings in Illumina by 30.7% in the first quarter. Global X Management Co. LLC now owns 1,281 shares of the life sciences company’s stock worth $219,000 after purchasing an additional 301 shares during the period. Institutional investors and hedge funds own 93.32% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.